Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Keith Rickert"'
Autor:
Mark Hutchinson, Jeffrey A. Ruffolo, Nantaporn Haskins, Michael Iannotti, Giuliana Vozza, Tony Pham, Nurjahan Mehzabeen, Harini Shandilya, Keith Rickert, Rebecca Croasdale-Wood, Melissa Damschroder, Ying Fu, Andrew Dippel, Jeffrey J. Gray, Gilad Kaplan
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Over the past two decades, therapeutic antibodies have emerged as a rapidly expanding domain within the field of biologics. In silico tools that can streamline the process of antibody discovery and optimization are critical to support a pipeline that
Externí odkaz:
https://doaj.org/article/fd2f8ba9525448dbbf68ca2c03eef55e
Autor:
Andrew Dippel, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, Qun Du, Reza Esfandiary, Erika Farmer, Andrew Garcia, Qing Li, Jia Lin, Weiyi Liu, LeeAnn Machiesky, Neil Mody, Arun Parupudi, Meagan Prophet, Keith Rickert, Kim Rosenthal, Song Ren, Harini Shandilya, Reena Varkey, Kevin Wons, Yuling Wu, Yueh-Ming Loo, Mark T. Esser, Nicole L. Kallewaard, Sarav Rajan, Melissa Damschroder, Weichen Xu, Gilad Kaplan
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTTo combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2. In order to maximize the th
Externí odkaz:
https://doaj.org/article/9f5679dc1264437881b543ce3007dd81
Autor:
Feng Chen, Kai Ma, Brian Madajewski, Li Zhuang, Li Zhang, Keith Rickert, Marcello Marelli, Barney Yoo, Melik Z. Turker, Michael Overholtzer, Thomas P. Quinn, Mithat Gonen, Pat Zanzonico, Anthony Tuesca, Michael A. Bowen, Larry Norton, J. Anand Subramony, Ulrich Wiesner, Michelle S. Bradbury
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
One of the major obstacles in nanoparticle-based therapy is to achieve tumour targeting, limiting non-specific accumulation of the nanoparticles. Here the authors propose the conjugation of anti-HER2 scFv fragments to the silica nanoparticles, increa
Externí odkaz:
https://doaj.org/article/d095ee381fd844ee881d6637c08ac110
Autor:
Andrew Dippel, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, Qun Du, Reza Esfandiary, Erika Farmer, Andrew Garcia, Qing Li, Jia Lin, Weiyi Liu, LeeAnn Machiesky, Neil Mody, Arun Parupudi, Meagan Prophet, Keith Rickert, Kim Rosenthal, Song Ren, Harini Shandilya, Reena Varkey, Kevin Wons, Yuling Wu, Yueh-Ming Loo, Mark T. Esser, Nicole L. Kallewaard, Sarav Rajan, Melissa Damschroder, Weichen Xu, Gilad Kaplan
Publikováno v:
mAbs. 15(1)
To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2. In order to maximize the therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af952b124fb9afa4945e1f0ae2458177
https://pubmed.ncbi.nlm.nih.gov/36476037
https://pubmed.ncbi.nlm.nih.gov/36476037
Autor:
Masato Iida, Peter Chase, Peter Hodder, Kazuhiro Fukasawa, Keith Rickert, Jason Cassaday, Mitsunori Koresawa, Hideya Komatani, Kenji Tanaka, Erica Stec, Toshimitsu Takagi
One of the challenges to develop time-resolved fluorescence resonance energy transfer (TR-FRET) assay for serine/threonine (Ser/Thr) protein kinase is to select an optimal peptide substrate and a specific phosphor Ser/Thr antibody. This report descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416ca4c99645861ffe09915f7f02ae10
https://europepmc.org/articles/PMC3532019/
https://europepmc.org/articles/PMC3532019/
Autor:
Paul J. Coleman, John D. Schreier, Christopher D. Cox, Mark E. Fraley, Robert M. Garbaccio, Carolyn A. Buser, Eileen S. Walsh, Kelly Hamilton, Robert B. Lobell, Keith Rickert, Weikang Tao, Ronald E. Diehl, Vicki J. South, Joseph P. Davide, Nancy E. Kohl, Youwei Yan, Lawrence Kuo, Thomayant Prueksaritanont, Chunze Li, Elizabeth A. Mahan, Carmen Fernandez-Metzler, Joseph J. Salata, George D. Hartman
Publikováno v:
Bioorganicmedicinal chemistry letters. 17(19)
3,5-diaryl-4,5-dihydropyrazoles were discovered to be potent KSP inhibitors with excellent in vivo potency. These enzyme inhibitors possess desirable physical properties that can be readily modified by incorporation of a weakly basic amine. Careful a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b61cc6362d9b2c03266cc85d1b2a289
https://pubmed.ncbi.nlm.nih.gov/17761419
https://pubmed.ncbi.nlm.nih.gov/17761419
Autor:
Mark E, Fraley, Kenneth L, Arrington, Carolyn A, Buser, Patrice A, Ciecko, Kathleen E, Coll, Christine, Fernandes, George D, Hartman, William F, Hoffman, Joseph J, Lynch, Rosemary C, McFall, Keith, Rickert, Romi, Singh, Sheri, Smith, Kenneth A, Thomas, Bradley K, Wong
Publikováno v:
Bioorganicmedicinal chemistry letters. 14(2)
Modifications to the basic side-chain of early lead structures of the indolyl quinolinone class of KDR kinase inhibitors resulted in improved pharmacokinetic and ancillary profiles. Specifically, compounds bearing 5-amido- and 5-sulphonamido-indolyl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52bf91289fc5d1bd3053dbfe34a27a98
https://pubmed.ncbi.nlm.nih.gov/14698157
https://pubmed.ncbi.nlm.nih.gov/14698157